Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Safety and Effectiveness of NRT6003 Injection in Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT06310590 is registered in ClinicalTrials.gov with Chengdu New Radiomedicine Technology Co. LTD. as lead sponsor.

NCT NCT06310590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06310590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Safety and Effectiveness of NRT6003 Injection in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Lead sponsor
Chengdu New Radiomedicine Technology Co. LTD.
Phase
Phase 1
Overall status
Completed
Start date
August 8, 2023
Completion date
June 10, 2025
Enrollment
40 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinoma